These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22984227)

  • 21. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
    Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
    van Luin M; Bannister WP; Mocroft A; Reiss P; Di Perri G; Peytavin G; Molto J; Karlson A; Castagna A; Beniowski M; Lundgren JD; Burger DM;
    Antivir Ther; 2009; 14(1):75-83. PubMed ID: 19320239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.
    Abdelhady AM; Desta Z; Jiang F; Yeo CW; Shin JG; Overholser BR
    J Clin Pharmacol; 2014 Jan; 54(1):87-96. PubMed ID: 24142869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz.
    Cusato J; Tempestilli M; Calcagno A; Vergori A; Piselli P; Antonucci M; Avataneo V; Palermiti A; Notari S; Antinori A; Di Perri G; Agrati C; D'Avolio A
    Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
    J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.
    Ximenez JP; Elias ABR; Nardotto GHB; Barroso PF; Bollela VR; Lanchote VL; Suarez-Kurtz G
    Br J Clin Pharmacol; 2022 Oct; 88(10):4585-4594. PubMed ID: 35514050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.
    Fabbiani M; Zaccarelli M; Grima P; Prosperi M; Fanti I; Colafigli M; D'Avino A; Mondi A; Borghetti A; Fantoni M; Cauda R; Di Giambenedetto S
    BMC Infect Dis; 2014 Jan; 14():26. PubMed ID: 24418191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S; Evans D; Zuma K; Okello V; Louwagie G
    Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz in the therapy of HIV infection.
    Rakhmanina NY; van den Anker JN
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):95-103. PubMed ID: 20001610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
    Brown LA; Jin J; Ferrell D; Sadic E; Obregon D; Smith AJ; Tan J; Giunta B
    PLoS One; 2014; 9(4):e95500. PubMed ID: 24759994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.
    Nwogu JN; Gandhi M; Owen A; Khoo SH; Taiwo B; Olagunju A; Berzins B; Okochi H; Tallerico R; Robertson K; Babalola CP
    AIDS; 2021 Oct; 35(12):1919-1927. PubMed ID: 34115651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
    Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
    Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
    South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ford N; Shubber Z; Pozniak A; Vitoria M; Doherty M; Kirby C; Calmy A
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):422-9. PubMed ID: 25850607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV antiretroviral drug Efavirenz induces anxiety-like and depression-like behavior in rats: evaluation of neurotransmitter alterations in the striatum.
    Cavalcante GI; Chaves Filho AJ; Linhares MI; de Carvalho Lima CN; Venâncio ET; Rios ER; de Souza FC; Vasconcelos SM; Macêdo D; de França Fonteles MM
    Eur J Pharmacol; 2017 Mar; 799():7-15. PubMed ID: 28188763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.